Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Director · Chief Executive Officer | March 10, 2026 | March 12, 2026 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRONWOOD PHARMACEUTICALS INC
Report date March 10, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,898,838 |
Reported balance
After 2026-03-10 transaction · row 1
1 source rowRow 1 · 2026-03-10 · Grant · Acquired 409,836 · Balance 1,898,838 F1: The restricted stock unit award, granted as an annual performance award, vests as to 33.33% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock unit award, granted as an annual performance award, vests as to 33.33% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
PLIANT THERAPEUTICS, INC.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2036-06-11 | Direct | 70,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 70,000 · Balance 70,000 F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACCELERON PHARMA INC
Report date November 19, 2021 · Filed November 22, 2021
Section 16 reporting ended · disclosed 2021-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Other · Disposed 6,044 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.64 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.99 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 8,185 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.53 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 3,222 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 19, 2021 Filed Nov 22, 2021 09:08 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 8,185 | Not disclosed Strike: $52.99 | Not disclosed |
DisclosureSEC source: 0001104659-21-142275 · tm2133601-9_4seq1.xml · derivative · entry 3 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,185 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:08 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 7,500 | Not disclosed Strike: $41.64 | Not disclosed |
DisclosureSEC source: 0001104659-21-142275 · tm2133601-9_4seq1.xml · derivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:08 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | OtherCommon Stock | 6,044 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-142275 · tm2133601-9_4seq1.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 16:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 104,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039159 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671,189 F1 · kind: The restricted stock unit award, granted as a new Chief Executive Officer award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| May 24, 2021 Filed May 26, 2021 16:01 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,716 | $12.25 | $21,021.00 |
DisclosureSEC source: 0001209191-21-035896 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · President and Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,499 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1, 2019. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 16:46 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 7,500 | $0.00 Strike: $40.61 | $0.00 |
DisclosureSEC source: 0001179110-21-004537 · edgar.xml · derivative · entry 6 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 16:46 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 200 | $121.23 | $24,246.00 |
DisclosureSEC source: 0001179110-21-004537 · edgar.xml · nonDerivative · entry 5 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,044 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.15 to $121.30 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 16:46 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 1,143 | $120.16 | $137,342.88 |
DisclosureSEC source: 0001179110-21-004537 · edgar.xml · nonDerivative · entry 4 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,244 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.83 to $120.74 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 16:46 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 4,030 | $119.36 | $481,020.80 |
DisclosureSEC source: 0001179110-21-004537 · edgar.xml · nonDerivative · entry 3 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,387 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.83 to $119.78 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 16:46 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 2,127 | $118.39 | $251,815.53 |
DisclosureSEC source: 0001179110-21-004537 · edgar.xml · nonDerivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,417 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.81 to $118.72 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 16:46 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 7,500 | $40.61 | $304,575.00 |
DisclosureSEC source: 0001179110-21-004537 · edgar.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 17:07 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 96,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023573 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · President and Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,215 F1 · kind: The restricted stock units, granted as a retention award, vest as to 50% of the shares of Class A Common Stock on each of May 19, 2022 and May 18, 2023. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 16:40 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 10,265 | $9.11 | $93,514.15 |
DisclosureSEC source: 0001209191-21-016070 · doc4.xml · nonDerivative · entry 3 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 471,577 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 16:40 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,838 | $9.11 | $16,744.18 |
DisclosureSEC source: 0001209191-21-016070 · doc4.xml · nonDerivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 481,842 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 16:40 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,582 | $9.11 | $23,522.02 |
DisclosureSEC source: 0001209191-21-016070 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,680 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:07 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 145,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013751 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,262 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 18:49 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 3,222 | $0.00 Strike: $115.53 | $0.00 |
DisclosureSEC source: 0001179110-21-001112 · edgar.xml · derivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,222 Underlying: Common Stock · 3,222 shares Expires 2031-01-29 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 18:49 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 1,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001112 · edgar.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,044 Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 16:49 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 99,988 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0001209191-20-063819 · doc4.xml · derivative · entry 3 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 99,988 shares Expires 2021-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, granted as an annual performance award, was exercisable in full. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 16:49 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Tax withholdingClass A Common Stock | 81,089 | $12.20 | $989,285.80 |
DisclosureSEC source: 0001209191-20-063819 · doc4.xml · nonDerivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,631 Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 16:49 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 99,988 | $9.89 | $988,881.32 |
DisclosureSEC source: 0001209191-20-063819 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reporting person acquired 1,885 shares of Class A common stock under the issuer's employee stock purchase plan on June 30, 2020. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:51 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 3,272 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001179110-20-009770 · edgar.xml · derivative · entry 7 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,272 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:51 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $0.00 Strike: $32.98 | $0.00 |
DisclosureSEC source: 0001179110-20-009770 · edgar.xml · derivative · entry 6 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant date. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:51 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 200 | $91.38 | $18,276.00 |
DisclosureSEC source: 0001179110-20-009770 · edgar.xml · nonDerivative · entry 5 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,422 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.34 to $91.42 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:51 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 13,896 | $90.64 | $1,259,533.44 |
DisclosureSEC source: 0001179110-20-009770 · edgar.xml · nonDerivative · entry 4 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,622 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.31 to $91.16 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:51 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 9,176 | $89.98 | $825,656.48 |
DisclosureSEC source: 0001179110-20-009770 · edgar.xml · nonDerivative · entry 3 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,518 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.31 to $90.30 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:51 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 3,272 | $30.17 | $98,716.24 |
DisclosureSEC source: 0001179110-20-009770 · edgar.xml · nonDerivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:51 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 20,000 | $32.98 | $659,600.00 |
DisclosureSEC source: 0001179110-20-009770 · edgar.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 11, 2020 Filed May 13, 2020 17:22 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,697 | $10.35 | $17,563.95 |
DisclosureSEC source: 0001209191-20-028903 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,847 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1, 2019. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 16:31 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 100,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014476 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,544 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to approximately 33.33% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 16:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,865 | $11.63 | $21,689.95 |
DisclosureSEC source: 0001209191-20-012490 · doc4.xml · nonDerivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,062 F3 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 16:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,312 | $11.63 | $26,888.56 |
DisclosureSEC source: 0001209191-20-012490 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,927 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 24, 2020 Filed Jan 28, 2020 16:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.02 | $0.00 |
DisclosureSEC source: 0001209191-20-005129 · doc4.xml · derivative · entry 3 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 20,000 shares Expires 2020-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| January 24, 2020 Filed Jan 28, 2020 16:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 20,000 | $12.71 | $254,200.00 |
DisclosureSEC source: 0001209191-20-005129 · doc4.xml · nonDerivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,239 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.33 to $12.98, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 24, 2020 Filed Jan 28, 2020 16:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 20,000 | $10.02 | $200,400.00 |
DisclosureSEC source: 0001209191-20-005129 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reporting person acquired 280 shares of Class A common stock under the issuer's employee stock purchase plan on December 31, 2019. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 17:48 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 8,185 | $0.00 Strike: $52.99 | $0.00 |
DisclosureSEC source: 0001179110-20-000779 · edgar.xml · derivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,185 Underlying: Common Stock · 8,185 shares Expires 2030-01-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 17:48 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 1,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000779 · edgar.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,422 Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 16:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 115,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061135 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,959 F1 · kind: The restricted stock units, granted as a special retention award, vest as to 100% of the shares of Class A Common Stock on November 18, 2021. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 16:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-19-048225 · doc4.xml · derivative · entry 5 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 130,000 shares Expires 2019-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 16:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001209191-19-048225 · doc4.xml · derivative · entry 4 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,944 Underlying: Class A Common Stock · 90,000 shares Expires 2019-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vested as to 40,000 shares of Class A common stock on each of October 24, 2011, December 21, 2012 and January 4, 2017 upon the issuer's achievement of regulatory or commercial milestones. The remainder of the option expires on September 7, 2019. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 16:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 220,000 | $9.24 | $2,032,800.00 |
DisclosureSEC source: 0001209191-19-048225 · doc4.xml · nonDerivative · entry 3 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,739 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.12 to $9.40, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 16:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 130,000 | $4.88 | $634,400.00 |
DisclosureSEC source: 0001209191-19-048225 · doc4.xml · nonDerivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 16:42 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 90,000 | $4.88 | $439,200.00 |
DisclosureSEC source: 0001209191-19-048225 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reporting person acquired 2,500 shares of Class A common stock under the issuer's employee stock purchase plan on June 28, 2019. Read SEC document |
| May 10, 2019 Filed May 14, 2019 16:13 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 4,055 | $10.53 | $42,699.15 |
DisclosureSEC source: 0001209191-19-029609 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,239 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of 100% of the reporting person's restricted stock units granted on July 31, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.41 to $10.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 01, 2019 Filed May 3, 2019 16:19 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 45,704 | $0.00 Strike: $11.78 | $0.00 |
DisclosureSEC source: 0001209191-19-027346 · doc4.xml · derivative · entry 2 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,704 Underlying: Class A Common Stock · 45,704 shares Expires 2029-05-01 F2 · derivative.exercise_date: The options, granted as a promotion grant, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of May 1, 2019. Read SEC document |
| May 01, 2019 Filed May 3, 2019 16:19 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-027346 · doc4.xml · nonDerivative · entry 1 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,294 F1 · kind: The restricted stock units, granted as a promotion award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:15 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 504 | Not disclosed Strike: $12.56 | Not disclosed |
DisclosureSEC source: 0001209191-19-023433 · doc4.xml · derivative · entry 10 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,504 Underlying: Class A Common Stock · 504 shares Expires 2024-03-03 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F8 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:15 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 962 | Not disclosed Strike: $11.65 | Not disclosed |
DisclosureSEC source: 0001209191-19-023433 · doc4.xml · derivative · entry 9 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,962 Underlying: Class A Common Stock · 962 shares Expires 2023-02-01 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F8 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:15 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 971 | Not disclosed Strike: $13.11 | Not disclosed |
DisclosureSEC source: 0001209191-19-023433 · doc4.xml · derivative · entry 8 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,971 Underlying: Class A Common Stock · 971 shares Expires 2022-02-01 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F8 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:15 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,988 | Not disclosed Strike: $9.89 | Not disclosed |
DisclosureSEC source: 0001209191-19-023433 · doc4.xml · derivative · entry 7 MCCOURT Thomas A · CIK 0001478448 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,988 Underlying: Class A Common Stock · 4,988 shares Expires 2021-02-01 F2 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F2 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F8 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.